Additionally, relative to patients with HR+/HER2− breast cancer, those with HER2+ disease had a lower risk of mortality (HR 0.86 (0.79–0.93), p < 0.001), and those with TN disease had a higher risk of mortality (HR 3.48 (3.22–3.76), p < 0.001). This evidence concerns the gene ERBB2 and breast carcinoma.